Cellectis Announces Closing of Follow-On Offering
April 10 2018 - 04:10PM
Business Wire
Regulatory News:
Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) (NASDAQ: CLLS –
EURONEXT GROWTH: ALCLS), a clinical-stage biopharmaceutical company
focused on developing immunotherapies based on gene-edited
allogeneic CAR T-cells, today announced the closing of its
underwritten offering of 5,646,000 American Depositary Shares
(“ADS”) at a public offering price of $31.00 per ADS. The net
proceeds to Cellectis from the offering are approximately $163.7
million, after deducting the estimated expenses related to the
offering and the underwriting discounts and commissions payable by
Cellectis. In connection with the offering, Cellectis granted the
underwriters a 30-day option to purchase up to an additional
846,900 ADSs. The ADSs are listed on the Nasdaq Global Market under
the symbol “CLLS” and Cellectis’ ordinary shares are listed on the
Euronext Growth market of Euronext in Paris under the symbol
“ALCLS”.
Goldman Sachs & Co. LLC, Citigroup and Barclays acted as
book-running managers for the offering. Nomura acted as lead
manager and Oppenheimer & Co. and Ladenburg Thalmann acted as
co-managers.
A shelf registration statement on Form F-3 (including a
prospectus) relating to Cellectis’ American Depositary Shares was
filed with the Securities and Exchange Commission (the “SEC”) and
has become effective. A copy of the prospectus supplement (and
accompanying prospectus) relating to the offering may be obtained
from Goldman Sachs & Co. LLC, Attention: Prospectus Department,
200 West Street, New York, NY 10282, or by telephone at (866)
471-2526 or by email at prospectus-ny@ny.email.gs.com, Citigroup
Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, or by telephone at (800)
831-9146 or Barclays Capital Inc., c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by
telephone at (888) 603-5847 or by email at
barclaysprospectus@broadridge.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction. In particular, no public offering of the
ADSs will be made in Europe.
Special Note Regarding Forward-Looking Statements
This press release contains “forward-looking” statements that
are based on our management’s current expectations and assumptions
and on information currently available to management.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Further information on the risk
factors that may affect company business and financial performance
is included in Cellectis’ Annual Report on Form 20-F for the year
ended December 31, 2017, and subsequent filings Cellectis makes
with the SEC from time to time. Except as required by law, we
assume no obligation to update these forward-looking statements
publicly, or to update the reasons actual results could differ
materially from those anticipated in the forward-looking
statements, even if new information becomes available in the
future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180410006425/en/
For further information, please contact:Media
contactsCellectis S.A.Jennifer Moore, 917-580-1088VP of
Communicationsmedia@cellectis.comorKCSA Strategic
CommunicationsCaitlin Kasunich,
212-896-1241ckasunich@kcsa.comorInvestor Relations
contactCellectis S.A.Simon Harnest, 646-385-9008VP of Corporate
Strategy and Financesimon.harnest@cellectis.com
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Mar 2023 to Mar 2024